21 results on '"Konishi, Noboru"'
Search Results
2. Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
- Author
-
Tanaka Nobumichi, Asakawa Isao, Anai Satoshi, Hirayama Akihide, Hasegawa Masatoshi, Konishi Noboru, and Fujimoto Kiyohide
- Subjects
Prostate cancer ,LDR-brachytherapy ,GU toxicity ,GI toxicity ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background To compare the periodical incidence rates of genitourinary (GU) and gastrointestinal (GI) toxicity in patients who underwent prostate low-dose-rate brachytherapy between the monotherapy group (seed implantation alone) and the boost group (in combination with external beam radiation therapy (EBRT)). Methods A total of 218 patients with a median follow-up of 42.5 months were enrolled. The patients were divided into 2 groups by treatment modality, namely, the monotherapy group (155 patients) and the boost group (63 patients). The periodical incidence rates of GU and GI toxicity were separately evaluated and compared between the monotherapy group and the boost group using the National Cancer Institute - Common Terminology Criteria for Adverse Events, version 3.0. To elucidate an independent factor among clinical and postdosimetric parameters to predict grade 2 or higher GU and GI toxicity in the acute and late phases, univariate and multivariate logistic regression analyses were carried out. Results Of all patients, 78.0% showed acute GU toxicity, and 7.8% showed acute GI toxicity, while 63.8% showed late GU toxicity, and 21.1% showed late GI toxicity. The incidence rates of late GU and GI toxicity were significantly higher in the boost group. Multivariate analysis showed that the International Prostate Symptom Score (IPSS) before seed implantation was a significant parameter to predict acute GU toxicity, while there were no significant predictive parameters for acute GI toxicity. On the other hand, combination with EBRT was a significant predictive parameter for late GU toxicity, and rectal volume (mL) receiving 100% of the prescribed dose (R100) was a significant predictive parameter for late GI toxicity. Conclusions The boost group showed higher incidence rates of both GU and GI toxicity. Higher IPSS before seed implantation, combination with EBRT and a higher R100 were significant predictors for acute GU, late GU and late GI toxicity.
- Published
- 2013
- Full Text
- View/download PDF
3. Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
- Author
-
Tanaka Nobumichi, Asakawa Isao, Fujimoto Kiyohide, Anai Satoshi, Hirayama Akihide, Hasegawa Masatoshi, Konishi Noboru, and Hirao Yoshihiko
- Subjects
Prostate cancer ,Brachytherapy ,PSA bounce ,Post-dosimetry ,UD90 (%) ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Background To clarify the significant clinicopathological and postdosimetric parameters to predict PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer. Methods We studied 200 consecutive patients who received LDR-brachytherapy between July 2004 and November 2008. Of them, 137 patients did not receive neoadjuvant or adjuvant androgen deprivation therapy. One hundred and forty-two patients were treated with LDR-brachytherapy alone, and 58 were treated with LDR-brachytherapy in combination with external beam radiation therapy. The cut-off value of PSA bounce was 0.1 ng/mL. The incidence, time, height, and duration of PSA bounce were investigated. Clinicopathological and postdosimetric parameters were evaluated to elucidate independent factors to predict PSA bounce in hormone-naïve patients who underwent LDR-brachytherapy alone. Results Fifty patients (25%) showed PSA bounce and 10 patients (5%) showed PSA failure. The median time, height, and duration of PSA bounce were 17 months, 0.29 ng/mL, and 7.0 months, respectively. In 103 hormone-naïve patients treated with LDR-brachytherapy alone, and univariate Cox proportional regression hazard model indicated that age and minimal percentage of the dose received by 30% and 90% of the urethra were independent predictors of PSA bounce. With a multivariate Cox proportional regression hazard model, minimal percentage of the dose received by 90% of the urethra was the most significant parameter of PSA bounce. Conclusions Minimal percentage of the dose received by 90% of the urethra was the most significant predictor of PSA bounce in hormone-naïve patients treated with LDR-brachytherapy alone.
- Published
- 2012
- Full Text
- View/download PDF
4. Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient's age and prostate volume.
- Author
-
Hori, Shunta, Tanaka, Nobumichi, Nakai, Yasushi, Morizawa, Yosuke, Tatsumi, Yoshihiro, Miyake, Makito, Anai, Satoshi, Fujii, Tomomi, Konishi, Noboru, Nakagawa, Yosinori, Hirao, Syuya, and Fujimoto, Kiyohide
- Subjects
PROSTATE cancer ,PROSTATE biopsy ,DIGITAL rectal examination ,NOMOGRAPHY (Mathematics) ,PROSTATE ,NEEDLE biopsy - Abstract
Background: The aim of this study is to evaluate the efficacy of two different Nara Urological Research and Treatment Group (NURTG) nomograms allocating 6–12 biopsy cores based on age and prostate volume. Materials and methods: From April 2006 to July 2014, a total of 1,605 patients who underwent initial prostate biopsy were enrolled. Based on a nomogram taking the patient's age and prostate volume into consideration, 6–12 biopsy cores were allocated. Two types of nomogram were used, for the former group (before March 2009) and latter group (March 2009 onward). Cancer detection rates in all patients and those with prostate-specific antigen values in the gray zone (4.0–10 ng/mL) were compared. Predictive parameters for detection of prostate cancer in gray-zone patients were also investigated. Results: The cancer detection rates in all patients and those in the gray zone were 48% and 38% in the former group and 54% and 41% in the latter group, respectively. The cancer detection rate in all patients was significantly higher in the latter group compared with the former group, but detection in gray-zone patients did not show a significant difference between the two groups (P=0.011 and P=0.37, respectively). Multivariate analysis indicated that age, digital rectal examination, prostate volume, transrectal ultrasonography findings, and volume/biopsy ratio were significant predictive parameters in gray-zone patients. The clinically insignificant cancer detection rate was significantly lower in the latter group compared with the former group (P=0.0008). Conclusion: The latter nomogram provided more acceptable detection rates of clinically significant and insignificant cancer than the former one, and we consider that an initial maximum 12-core transrectal ultrasound-guided needle biopsy may be sufficient for prostate cancer diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012.
- Author
-
Nobumichi Tanaka, Yasushi Nakai, Makito Miyake, Satoshi Anai, Takeshi Inoue, Tomomi Fujii, Noboru Konishi, Kiyohide Fujimoto, Tanaka, Nobumichi, Nakai, Yasushi, Miyake, Makito, Anai, Satoshi, Inoue, Takeshi, Fujii, Tomomi, Konishi, Noboru, and Fujimoto, Kiyohide
- Subjects
PROSTATE cancer ,JAPANESE people ,NARA Medical University (Japan) ,RADIOTHERAPY ,PROSTATECTOMY ,HEALTH ,ANTINEOPLASTIC agents ,COMBINED modality therapy ,PROSTATE tumors - Abstract
Background: To assess the trends in risk classification and primary therapy of Japanese prostate cancer patients who were diagnosed between 2004 and 2012.Methods: A total of 7768 patients who were newly diagnosed with prostate cancer at Nara Medical University and its 23 affiliated hospitals between 2004 and 2012 were enrolled. The trends in risk classification and primary therapy in 2004-2006 (prior period), 2007-2009 (middle period), and 2010-2012 (latter period) were compared.Results: The proportion of high-risk and worse patients significantly decreased in the latter period compared to the prior period (p < 0.001), while that of intermediate-risk patients significantly increased over the years (p < 0.001). The proportion of primary androgen deprivation therapy (PADT) was 50% in the prior period, 40% in the middle period, and 30% in the latter period, respectively. The proportions of radiation therapy and active surveillance significantly increased. The proportion of radical prostatectomy remained similar over these periods (30%). The primary therapy was significantly different between the three periods (p < 0.001).Conclusions: High-risk patients significantly decreased in the latter period. The use of PADT also significantly decreased, while radiation therapy and active surveillance significantly increased over these periods. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
6. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
- Author
-
Tanaka, Nobumichi, Asakawa, Isao, Nakai, Yasushi, Miyake, Makito, Anai, Satoshi, Fujii, Tomomi, Hasegawa, Masatoshi, Konishi, Noboru, and Fujimoto, Kiyohide
- Subjects
PROSTATE-specific antigen ,LOW dose rate brachytherapy ,PROSTATE cancer treatment ,PROSTATE cancer patients ,CANCER radiotherapy ,TESTOSTERONE ,PROSTATE tumors ,RADIATION doses ,RADIOISOTOPE brachytherapy ,RADIOTHERAPY ,TREATMENT effectiveness - Abstract
Background: To compare the PSA value at the last follow-up of patients who underwent prostate low-dose rate brachytherapy (LDR-BT) with that of patients who underwent intensity-modulated radiation therapy (IMRT).Methods: A total of 610 prostate cancer patients (cT1c-3bN0M0) were enrolled, and 445 of them underwent LDR-BT, while 165 received IMRT (74-76 Gy). The median follow-up period of these two groups was 75 months (LDR-BT) and 78 months (IMRT), respectively. We also evaluated the biochemical recurrence (BCR)-free rate using two definitions (Phoenix definition and PSA ≥ 0.2 ng/mL).Results: The percentage of patients who achieved PSA < 0.2 ng/mL at the last follow-up was 77.5% in the LDR-BT group and 49.7% in the IMRT group (p < 0.001). Among patients with a normal testosterone level at the last follow-up, the percentage of those who achieved PSA < 0.2 ng/mL at the last follow-up was 79.2% in the LDR-BT group and 32.1% in the IMRT group (p < 0.001). The 5-year BCR-free rate by the Phoenix definition in the IMRT and LDR-BT groups was 89.5 and 95.0% (p < 0.001), respectively. On the other hand, the 5-year BCR-free rate using the definition of PSA ≥ 0.2 ng/mL was 59.1 and 80.1% in the IMRT and LDR-BT groups, respectively (p < 0.001).Conclusions: The PSA value at the last follow-up of LDR-BT was significantly lower than that of IMRT, and this result was particularly marked in patients with a normal testosterone level at the last follow-up. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
7. Transperineal template-guided saturation biopsy aimed at sampling one core for each milliliter of prostate volume: 103 cases requiring repeat prostate biopsy.
- Author
-
Yasushi Nakai, Nobumichi Tanaka, Satoshi Anai, Makito Miyake, Shunta Hori, Yoshihiro Tatsumi, Tomomi Fujii, Noboru Konishi, Kiyohide Fujimoto, Nakai, Yasushi, Tanaka, Nobumichi, Anai, Satoshi, Miyake, Makito, Hori, Shunta, Tatsumi, Yoshihiro, Morizawa, Yosuke, Fujii, Tomomi, Konishi, Noboru, and Fujimoto, Kiyohide
- Subjects
BIOPSY ,PROSTATE cancer ,RETROSPECTIVE studies ,RADIOISOTOPE brachytherapy ,NEEDLE biopsy ,PROSTATE-specific antigen ,ANTHROPOMETRY ,PERINEUM ,PROSTATE ,PROSTATE tumors ,ULTRASONIC imaging - Abstract
Background: We evaluated the cancer detection rate of prostate cancer using transperineal template-guided saturation biopsy aimed at sampling one core for each milliliter of prostate volume for patients requiring repeated prostate biopsies.Methods: In total, 103 consecutive patients with repeated prostate biopsies were enrolled in this retrospective study. The number of biopsy cores was defined by prostate volume. In principle, one biopsy core covered 1 mL of prostate volume. We used a prostate brachytherapy template with a 5-mm grid and adopted a transperineal needle biopsy.Results: The median age, prostate-specific antigen level, and prostate volume were 69 (range, 37-83) years, 9.2 (range, 1.9-107) ng/mL, and 34.7 (range, 18-76.7) mL, respectively. The median number of biopsy cores was 37 (range, 18-75 cores). Fifty-three patients (51.5%) were diagnosed with prostate cancer. The Gleason score was 6, 7, and 8-10 in 24.5, 64.2 and 11.3% patients, respectively. Forty-two patients (79.2%) were diagnosed with clinically significant PCa. Acute urinary retention was detected in 2 patients (1.9%).Conclusions: Transperineal template-guided saturation biopsy with one core per milliliter of prostate volume helped achieve a high cancer detection rate and high significant cancer detection rate with acceptable biopsy-associated adverse events. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
8. The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram.
- Author
-
Tanaka, Nobumichi, Shimada, Keiji, Nakagawa, Yoshinori, Hirao, Shuya, Watanabe, Shuji, Miyake, Makito, Anai, Satoshi, Hirayama, Akihide, Konishi, Noboru, and Fujimoto, Kiyohide
- Subjects
PROSTATE biopsy ,ANTIGENS ,ENDORECTAL ultrasonography ,LOGISTIC regression analysis ,UNIVARIATE analysis - Abstract
Background: To elucidate the optimal number of prostate biopsy cores using a nomogram allocating 6-12 biopsy cores, the number generally used in daily practice, based on age and prostate volume (PV). Methods: We enrolled 936 patients who received an initial prostate biopsy from April 2006 to January 2009. A number of 6-12 biopsy cores was allocated based on age and PV Nara Urological Research and Treatment Group (NURTG) nomogram. To elucidate the predictive parameters of cancer detection in patients with a prostate specific antigen (PSA) value in the gray zone, univariate and multivariate logistic regression analysis were carried out. Results: The total cancer detection rate and the cancer detection rate in the PSA gray zone (4.1-10.0 ng/mL) were 48.0 and 37.6 %, respectively. The cancer detection rates in the gray zone stratified by patient age of ≤59, 60-64, 65-69, 70-74, 75-79, and ≥80 years were 28.4, 35.0, 26.9, 37.9, 45.7, and 54.8 %, respectively. The significant predictive parameters of cancer detection in the gray zone were age, volume biopsy ratio (VBR: PV divided by number of biopsy cores), PSA density (PSAD), digital rectal examination findings, and transrectal ultrasound findings in univariate analyses. Finally, age, VBR, and PSAD were independent parameters to predict cancer detection in the gray zone. The adverse event profile was acceptable. Conclusions: Our present study revealed that the cancer detection rate using the NURTG nomogram allocating 6-12 biopsy cores, the number generally used in daily practice, based on age and PV, could provide similar efficacy as previous studies involving more biopsy cores. In older patients the number of biopsy cores could be reduced. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -.
- Author
-
Tanaka, Nobumichi, Torimoto, Kazumasa, Asakawa, Isao, Miyake, Makito, Anai, Satoshi, Hirayama, Akihide, Hasegawa, Masatoshi, Konishi, Noboru, and Fujimoto, Kiyohide
- Subjects
ADRENERGIC receptors ,RADIOISOTOPE brachytherapy ,PROSTATE cancer patients ,URINARY tract infections ,ARTIFICIAL implants - Abstract
Background To evaluate the effect of two different alpha-1 adrenoceptor antagonists on lower urinary tract symptoms in patients who underwent LDR-brachytherapy. Methods A total of 141 patients who had been clinically diagnosed with localized prostate cancer and underwent LDR-brachytherapy between were enrolled. Patients were randomized and allocated to two groups (silodosin 8 mg vs. naftopidil 75 mg). The primary endpoint was a change in the international prostate symptom score (IPSS) at 3 months after seed implantation. Secondary endpoints included the recovery rate of IPSS at 12 months after seed implantation, the change in IPSS and overactive bladder symptom score, uroflowmetric parameters, and frequency volume chart (FVC). To determine independent variables that can predict IPSS recovery, logistic regression analysis was carried out. Results The mean change in the IPSS at 3 months after seed implantation in both groups was ⊿10.6 (naftopidil) and ⊿10.4 (silodosin), respectively. There was not a significant difference between the two groups (p=0.728). An increase in urinary frequency and a decrease in total urinated volume and mean voided volume were observed in FVC for 12 months after seed implantation. Multivariate analysis revealed that the urethral dose (UD30) was an independent predictive parameter of IPSS recovery. Patients with UD30 < 200Gy showed a higher recovery rate of IPSS at 12 months after seed implantation. Conclusion There was no significant difference of serial change in IPSS between silodosin and naftopidil during the first year after seed implantation. A lower dose on the urethra was an independent predictor of IPSS recovery at 12 months after seed implantation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Computer-Assisted Three-Dimensional Analysis of Multifocal/Multicentric Prostate Cancer.
- Author
-
Fujii, Tomomi, Ishida, Eiwa, Shimada, Keiji, Hirao, Kazuya, Tanaka, Nobumichi, Fujimoto, Kiyohide, and Konishi, Noboru
- Subjects
PROSTATE cancer ,COMPUTERS in medicine ,TISSUE wounds ,CANCER genetics ,DNA microarrays ,PROSTATECTOMY - Abstract
In order to study multiple contiguous prostate cancer lesions, we constructed computer-assisted, three-dimensional models of multifocal prostate cancer specimens obtained by radical prostatectomy. We then examined the genetic heterogeneity among the specimens by DNA microarray analysis. Cancer foci with high Gleason patterns were found to occur de novo, whereas those with low Gleason patterns occurred contiguously with cancers of low Gleason patterns. Three-dimensional analysis showed that distinct, noncontiguous cancerous foci were genetically independent and multicentric. In contrast some contiguous multifocal lesions had the same genetic origin. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)--a comparison between 2004-2006 and 2007-2009.
- Author
-
Nobumichi Tanaka, Akihide Hirayama, Tatsuo Yoneda, Katsunori Yoshida, Keiji Shimada, Noboru Konishi, Kiyohide Fujimoto, Tanaka, Nobumichi, Hirayama, Akihide, Yoneda, Tatsuo, Yoshida, Katsunori, Shimada, Keiji, Konishi, Noboru, and Fujimoto, Kiyohide
- Subjects
PROSTATE cancer ,THERAPEUTICS ,HYPERANDROGENISM ,NARA Medical University (Japan) ,PROSTATE tumors treatment ,THERAPEUTIC use of antineoplastic agents ,RELATIVE medical risk ,RESEARCH ,ANTIANDROGENS ,PROSTATECTOMY ,RESEARCH methodology ,RETROSPECTIVE studies ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,TUMOR grading ,PROSTATE tumors - Abstract
Background: To assess the trends of risk classification and primary therapy in Japanese patients who were diagnosed with prostate cancer between 2004-2006 and 2007-2009.Methods: A total of 4752 patients who were newly diagnosed with prostate cancer at Nara Medical University and its 23 affiliated hospitals between 2004 and 2009 were enrolled. The differences in risk classification and primary therapy were compared in patients who were newly diagnosed between 2004-2006 (prior period) and 2007-2009 (latter period).Results: The proportion of patients with a high or greater risk significantly decreased in the latter period compared to the prior period (p < 0.001). The proportion of primary androgen deprivation therapy (PADT) was 50% in the prior period, and 40% in the latter period. On the other hand, the proportion of radiation therapy was 14% in the prior period, but 24% in the latter period. The proportion of radical prostatectomy was the same in the two periods (30%). The primary therapy was significantly different between the two periods (p < 0.001).Conclusions: Higher risk patients significantly decreased in the latter period compared to the prior period. The use of PADT also significantly decreased in the latter period. However, there were still higher risk patients in Japan, and the use of PADT was still common in patients with localized prostate cancer or locally advanced prostate cancer in Japan. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
12. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: Our first series of 100 patients.
- Author
-
Tanaka, Nobumichi, Asakawa, Isao, Kondo, Hideaki, Tanaka, Motoyoshi, Fujimoto, Kiyohide, Hasegawa, Masatoshi, Konishi, Noboru, and Hirao, Yoshihiko
- Subjects
CANCER patients ,PROSTATE cancer ,CANCER treatment ,MEDICAL radiology ,HOSPITAL radiological services - Abstract
Objectives: To assess our initial experience in the treatment of localized prostate cancer using low-dose-rate brachytherapy (LDR-brachytherapy) with iodine-125. Methods: One-hundred consecutive patients received LDR-brachytherapy between July 2004 and October 2006. Seventy-six patients were treated with seed implantation alone, whereas 24 patients were treated with a combination of brachytherapy and external beam radiotherapy. The minimal percentage of the dose received by 90% of the prostate gland (%D90), the percentage prostate volume receiving 100% of the prescribed minimal peripheral dose (V100), and the operation time were compared among every 10 consecutive patients. Results: The means of %D90 and V100 were 109.6% and 93.4%, respectively. When compared with the first 10 patients, both D90 and V100 showed significant improvement in the following 10 consecutive patients. Similarly, the mean operation time decreased significantly according to the accumulated number of patients. Conclusions: Our initial experience with the first 100 cases suggests that LDR-brachytherapy needs accumulation of many more patients to obtain high-quality post-implant dosimetric outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
13. Molecular pathology of prostate cancer.
- Author
-
Konishi, Noboru, Shimada, Keiji, Ishida, Eiwa, and Nakamura, Mitsutoshi
- Subjects
- *
PROSTATE cancer , *ETIOLOGY of diseases , *PROSTATE-specific antigen , *CANCER patients , *PATHOLOGY - Abstract
The incidence of prostate cancer has increased in Japan recently and is developing into a life-threatening disease for many Japanese men. This is a result of several convergent factors including the adoption of a Western lifestyle, the widespread use of prostate-specific antigen (PSA) testing, and an increased population of advanced years in Japanese men. Although there is much information to date relating to molecular events underlying the etiology of prostate cancer, it is still unclear as to how and when these genetic alterations occur in each step of tumorigenesis. One fruitful area of investigation has been in the analysis of chromosomal abnormalities commonly observed in prostate cancer. However, no single candidate gene has been definitely identified in cancer initiation and/or progression; in addition, less research has been devoted to understanding the molecular events that underlie tumor histogenesis in terms of likely precursor lesions, such as prostatic intraepithelial neoplasia (PIN). This article reviews the current knowledge of the molecular pathology of prostate cancer, including its histogenesis, genetic and epigenetic alterations, and hereditary factors. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
14. Autopsy case of prostate cancer with multiple endocrine neoplasia 2A.
- Author
-
Ishida, Eiwa, Nakamura, Mitsutoshi, Shimada, Keiji, Matsuyoshi, Syuichi, Tada, Kazuhiro, Okajima, Eijiro, Fujimoto, Kiyohide, and Konishi, Noboru
- Subjects
AUTOPSY ,PROSTATE cancer ,PHEOCHROMOCYTOMA ,NEUROENDOCRINE tumors ,METASTASIS ,IMMUNOGLOBULINS ,PATHOLOGY ,IMMUNOHISTOCHEMISTRY - Abstract
We describe an autopsy case of a 65-year-old man with prostate cancer accompanied by multiple endocrine neoplasia 2A (MEN 2A), including malignant pheochromocytomas, thyroid medullary carcinomas and parathyroid hyperplasia. Metastatic lesions from the prostate primary were identified using immunohistochemistry for prostate specific antigen within both primary and metastatic pheochromocytomas in the liver. To investigate the affinity of prostate cancer for pheochromocytoma cells, immunohistochemistry was carried out using a number of antibodies and both tumors were positive for N-cadherin. Interestingly, pheochromocytomas, thyroid medullary carcinomas and prostate cancer were all positive for the anti-RET antibody. The immunohistochemical results suggest that the cell affinity may, in part, result from cell–cell adhesion via N-cadherin. Although prostate cancer is rarely associated with MEN,RETactivation may have participated in the tumorigenesis of this case. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
15. Distribution and secretory pathways of prostate specific antigen, α1 -antichymotrypsin and prostate secretory granules in prostate cancers.
- Author
-
Ishida, Eiwa, Nakamura, Mitsutoshi, Shimada, Keiji, Kishi, Munehiro, Nakaoka, Shingo, and Konishi, Noboru
- Subjects
PROSTATE cancer ,EPITHELIAL cells ,CANCER cells ,CYTOPLASM - Abstract
Using 19 radical prostatectomy specimens, we studied the histological distribution of free prostate specific antigen (PSA), total PSA, α
1 -antichymotrypsin (ACT) and prostate secretory granules (PSG) in both normal and cancerous cells of the prostate. After glutaraldehyde fixation, numerous fine eosinophilic droplets of PSG could be found mainly in the apical portions of normal acinous epithelial cells, but was markedly decreased in cancer cells. With antibodies against free PSA, normal acinous cells were granularly positive in the apical portion of the epithelium, which corresponded to the PSG, whereas cancer cells were diffusely positive. With antibodies against ACT, normal duct cells and cancer cells were often positive, but few normal acinous cells were positive. Presumably, these findings indicate that free PSA is secreted into the lumen as PSG in normal glands, but not by the same pathway in cancers where free PSA appears to accumulate due to a decrease of PSG, then leak into the blood producing complexed PSA to some extent in the cytoplasm. One factor analysis of variance (anova) on the correlation of tumor differentiation or Gleason score with serum values of total PSA, free PSA and a free/total PSA ratio demonstrated no significant links. Elucidation of secretory mechanisms should provide better comprehension of various PSA indices for prostate cancer screening. [ABSTRACT FROM AUTHOR]- Published
- 2003
- Full Text
- View/download PDF
16. Immunohistochemical Analysis of Midkine Expression in Human Prostate Carcinoma.
- Author
-
Konishi, Noboru, Nakamura, Mitsutoshi, Nakaoka, Shingo, Hiasa, Yoshio, Cho, Masaki, Uemura, Hirotsugu, Hirao, Yoshihiko, Muramatsu, Takashi, and Kadomatsu, Kenji
- Subjects
- *
GROWTH factors , *PROSTATE cancer , *IMMUNOHISTOCHEMISTRY , *CYTOKINES , *CARCINOGENESIS - Abstract
Midkine (MK) is a growth/differentiation factor frequently expressed at high levels in some types of human malignancies. To investigate whether MK is a useful marker in prostate carcinogenesis, immunohistochemical analysis was performed on samples of both latent and clinical prostate cancers of various stages, as well as on specimens of normal gland and prostatic intraepithelial neoplasia (PIN). Of the 80 clinical cancers examined, 69 specimens (86.3%) were immunoreactive for MK, with metastatic lesions generally showing higher expression than the corresponding primaries; normal prostate tissues were negative or showed only weak staining. Midkine was also detected in 12 of 15 latent cancers (80%) and in 12 of 16 cases of PIN (75%). In sections of whole prostate, MK showed variable expression through tumorous sections, probably in reflection of heterogeneous cell populations. The results demonstrate the possible value of MK as a marker for early and latent disease, as well as for more advanced clinical stages of prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
17. Expression of pepsinogen II with androgen and estrogen receptors in human prostate carcinoma.
- Author
-
Konishi, Noboru, Nakaoka, Shingo, Matsumoto, Kyoichi, Nakamura, Mitsutoshi, Kuwashima, Shin-ichi, Hiasa, Yoshio, Cho, Masaki, Uemura, Hirotsugu, and Hirao, Yoshihiko
- Subjects
- *
PEPSINOGEN , *ANDROGENS , *ESTROGEN receptors - Abstract
The expression of pepsinogen II (PG II), an aspartyl proteinase usually involved in the digestion of proteins in the stomach, was immunohistochemically investigated in conjunction with androgen (AR) and estrogen receptor (ER) status in prostate adenocarcinomas. Of a total of 38 samples obtained from radical prostatectomies, 23 tumors (60.5%) were positive for PG II and there was a significant positive correlation to the expression of AR but not to ER. Cells positive for PG II were localized mainly to the peripheral zones of tumorous glands which, in normal prostate, are negative, and in areas also expressing AR. In addition, a significant correlation between AR and ER was detected in the prostate carcinomas examined, which suggests a hormone-dependent status. On the basis of these results, PG II expression might be closely related to hormonal alterations associated with the development of prostate tumors. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
18. Expression of KAI1 in paraffin-embedded normal, hyperplastic and neoplastic prostate and prostate carcinoma cell lines.
- Author
-
Ward, Jerrold M., Konishi, Noboru, Ohshima, Masato, Lamb, Patricia W., Jorcyk, Cheryl L., and Barrett, J. Carl
- Subjects
- *
METASTASIS , *PROSTATE cancer , *IMMUNOCHEMISTRY - Abstract
Examines the tumor metastasis suppressor gene in paraffin-embedded normal, hyperplastic and neoplastic prostate carcinoma cell lines. Visualization of cells by immunochemistry; Immunoreactivity of the membrane antigen in cell lines; Details on the pretreatment with trypsin enhanced immunoreactivity.
- Published
- 1998
- Full Text
- View/download PDF
19. Changes in lower urinary tract symptoms and quality of life after salvage radiotherapy for biochemical recurrence of prostate cancer.
- Author
-
Miyake, Makito, Tanaka, Nobumichi, Asakawa, Isao, Tatsumi, Yoshihiro, Nakai, Yasushi, Anai, Satoshi, Torimoto, Kazumasa, Aoki, Katsuya, Yoneda, Tatsuo, Hasegawa, Masatoshi, Konishi, Noboru, and Fujimoto, Kiyohide
- Subjects
- *
URINARY tract infections , *COMMUNICABLE diseases , *QUALITY of life , *BIOREACTORS , *PROSTATE cancer - Abstract
Background and purpose The aim of this study was to evaluate chronologic changes in lower urinary tract symptoms (LUTS), health-related (HR) quality of life (QOL), and disease-specific QOL during the first 12 months after salvage radiotherapy (SRT) for biochemical recurrence of prostate cancer in patients who underwent radical prostatectomy. Materials and methods In 81 patients who received SRT (70 Gy/35fr/7 weeks), International Prostate Symptom Score (IPSS), 36-Item Short Form scores, and UCLA-Prostate Cancer Index (UCLA-PCI) were recorded before, during, and immediately after SRT, and 1–12 months after the completion of SRT. Results The total IPSS and storage symptom-related sum were significantly increased following initiation of SRT, and returned to the baseline 6 months after SRT. For three of eight domains of HRQOL, and the physical component summary score showed transient deterioration in the period between completion of SRT and 1 month following SRT. The UCLA-PCI for urinary function/bother and bowel function/bother was affected until 1–6 months after SRT. Conclusions This is the first report to concurrently evaluate detailed chronologic changes in LUTS and QOL in patients who received SRT. Knowledge of changes in LUTS and QOL outcomes associated with SRT may influence treatment recommendations and enable patients to make better-informed decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer.
- Author
-
Fujii, Tomomi, Shimada, Keiji, Tatsumi, Yoshihiro, Fujimoto, Kiyohide, and Konishi, Noboru
- Subjects
- *
SYNDECANS , *MICRORNA , *CELL proliferation , *PROSTATE cancer treatment , *CELL differentiation , *MOLECULAR weights - Abstract
MicroRNAs (miRNAs) are short (19–24 nt), low molecular weight RNAs that play important roles in the regulation of target genes associated with cell proliferation, differentiation, and development, by binding to the 3′-untranslated region of the target mRNAs. In this study, we examined the expression of miRNA-126 (miR-126) and miR-149 in prostate cancer, and investigated the molecular mechanisms by which they affect syndecan-1 in prostate cancer. Functional analysis of miR-126 and miR-149 was conducted in the prostate cancer cell lines, PC3, Du145, and LNCaP. The expression levels of SOX2, NANOG, Oct4, miR-126 and miR-149 were evaluated by quantitative RT-PCR. After silencing syndecan-1, miR-126, and/or miR-149 in the PC3 cells, cell proliferation, senescence, and p21 induction were assessed using the MTS assay, senescence-associated β -galactosidase (SA- β -Gal) assay, and immunocytochemistry, respectively. Compared to the Du145 and LNCaP cells, PC3 cells exhibited higher expression of syndecan-1. When syndecan-1 was silenced, the PC3 cells showed reduced expression of miR-126 and miR-149 most effectively. Suppression of miR-126 and/or miR-149 significantly inhibited cell growth via p21 induction and subsequently, induced senescence. The mRNA expression levels of SOX2, NANOG, and Oct4 were significantly increased in response to the silencing of miR-126 and/or miR-149. Our results suggest that miR-126 and miR-149 are associated with the expression of syndecan-1 in prostate cancer cells. These miRNAs promote cell proliferation by suppressing SOX2, NANOG, and Oct4. The regulation of these factors by miR-126 and miR-149 is essential for syndecan-1-mediated development of androgen-refractory prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Variations in health-related quality of life in Japanese men who underwent iodine-125 permanent brachytherapy for localized prostate cancer
- Author
-
Tanaka, Nobumichi, Fujimoto, Kiyohide, Asakawa, Isao, Hirayama, Akihide, Yoneda, Tatsuo, Yoshida, Katsunori, Hirao, Yoshihiko, Hasegawa, Masatoshi, and Konishi, Noboru
- Subjects
- *
PROSTATE cancer treatment , *QUALITY of life , *RADIOISOTOPE brachytherapy , *HEALTH outcome assessment ,THERAPEUTIC use of iodine isotopes - Abstract
Abstract: Purpose: The purpose of this study was to prospectively assess the variations in health-related quality of life (HR-QoL) in patients who underwent low–dose rate prostate brachytherapy using iodine-125 seed source during the first year after seed implantation. Methods and Materials: Between July 2004 and December 2006, 109 patients underwent low–dose rate brachytherapy. The Medical Outcomes study 36-Item Short Form; the University of California, Los Angeles-Prostate Cancer Index; and the International Index of Erectile Function-5 were evaluated before and at 1, 3, 6, and 12 months after seed implantation. Results: In Medical Outcomes study 36-Item Short Form analyses and the HR-QoL scores were well preserved during the first year after seed implantation. In the University of California, Los Angeles-Prostate Cancer Index analyses, the urinary function and bother scores showed significant decrease during 6 months after seed implantation. The bowel function and bother scores showed significant decrease at 3 months after seed implantation. The sexual function score showed significant decrease at 3, 6, and 12 months after seed implantation, whereas the sexual bother score showed no change during the first year. The International Index of Erectile Function-5 score dramatically decreased at 1, 3, 6, and 12 months after seed implantation. Conclusions: The general HR-QoL in the patients who underwent seed implantation was well preserved during the first year after seed implantation, whereas the urinary, bowel, and sexual function and bother scores showed transient deterioration during the first year after seed implantation. Especially, sexual function showed significant deterioration in Japanese men after seed implantation. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.